NOS2

Summary

NOS2 (nitric oxide synthase 2, HGNC:7873) is a protein-coding gene on chromosome 17q11.2, encoding Nitric oxide synthase, inducible (P35228). Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body.

Nitric oxide is a reactive free radical which acts as a biologic mediator in several processes, including neurotransmission and antimicrobial and antitumoral activities. This gene encodes a nitric oxide synthase which is expressed in liver and is inducible by a combination of lipopolysaccharide and certain cytokines. Three related pseudogenes are located within the Smith-Magenis syndrome region on chromosome 17.

Source: NCBI Gene 4843 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• Clinical variants (ClinVar): 213 total
• GTEx eGene: eQTL in 43 tissues, sQTL in 3 (q < 0.05)
• Drug target: yes — 2 curated mechanism-of-action drugs, 1 via a complex or family; 10 molecules with ChEMBL bioactivity (top 3% of genes corpus-wide)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.86 (unconstrained)
• MANE Select transcript: NM_000625
• Interaction hub: 2,454 STRING partners (top 4% of genes corpus-wide)
• Notable: 213 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7873
Approved symbol	NOS2
Name	nitric oxide synthase 2
Location	17q11.2
Locus type	gene with protein product
Status	Approved
Aliases	iNOS, NOS, HEP-NOS
Ensembl gene	ENSG00000007171
Ensembl biotype	protein_coding
OMIM	163730
Entrez	4843

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 5 protein_coding, 3 nonsense_mediated_decay, 1 retained_intron

MANE Select: ENST00000313735

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1

ENST00000313735, ENST00000646938, ENST00000697337, ENST00000697338, ENST00000697339, ENST00000697340, ENST00000697341, ENST00000886820, ENST00001139812

RefSeq mRNA: 1 — MANE Select: NM_000625 NM_000625

CCDS: CCDS11223

Canonical transcript exons

ENST00000313735 — 27 exons

Exon	Start	End
ENSE00000406697	27769535	27769584
ENSE00000704507	27773161	27773243
ENSE00000704841	27778690	27778791
ENSE00000705157	27782015	27782106
ENSE00000946394	27770913	27771017
ENSE00001126885	27765535	27765716
ENSE00001126938	27778882	27779056
ENSE00001126954	27781036	27781177
ENSE00001251604	27763981	27764144
ENSE00001251789	27780767	27780906
ENSE00001292830	27762798	27763005
ENSE00001302992	27798700	27798882
ENSE00001304187	27761144	27761231
ENSE00001309781	27768977	27769151
ENSE00001310933	27766510	27766588
ENSE00001310953	27788809	27788931
ENSE00001312003	27774257	27774451
ENSE00001312300	27782944	27783106
ENSE00001322003	27758881	27759075
ENSE00001327291	27789604	27789688
ENSE00001327457	27772308	27772452
ENSE00001347743	27767705	27767837
ENSE00001347946	27787678	27787826
ENSE00001704085	27756766	27757353
ENSE00001842263	27800339	27800529
ENSE00002334691	27760030	27760178
ENSE00002411104	27760623	27760744

Expression profiles

Bgee: expression breadth ubiquitous, 153 present calls, max score 94.55.

FANTOM5 (CAGE): breadth broad, TPM avg 8.9028 / max 1337.0827, expressed in 242 samples.

Highest expression (Bgee): cartilage tissue, olfactory segment of nasal mucosa, mucosa of paranasal sinus, mucosa of transverse colon, rectum.

Genetic regulation across tissues (GTEx eQTL / sQTL)

NOS2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 43 tissues and its splicing (sQTL) in 3 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 46 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Nerve Tibial	eqtl	7.7e-167	-1.07	17:27879388:C:A
Skin Sun Exposed Lower leg	eqtl	2.0e-125	-1.09	17:27879388:C:A
Skin Not Sun Exposed Suprapubic	eqtl	1.9e-84	-1.04	17:27879388:C:A
Artery Tibial	eqtl	2.7e-79	-0.87	17:27879388:C:A
Esophagus Muscularis	eqtl	8.2e-79	-1.01	17:27879388:C:A
Adipose Subcutaneous	eqtl	1.4e-72	-0.82	17:27879388:C:A
Esophagus Gastroesophageal Junction	eqtl	6.0e-67	-0.99	17:27879388:C:A
Muscle Skeletal	eqtl	4.6e-59	-0.72	17:27879388:C:A
Brain Nucleus accumbens basal ganglia	eqtl	5.3e-54	-0.97	17:27879388:C:A
Brain Cerebellar Hemisphere	eqtl	2.7e-45	-0.76	17:27879388:C:A
Brain Cerebellum	eqtl	2.9e-44	-0.82	17:27879388:C:A
Breast Mammary Tissue	eqtl	1.5e-42	-0.83	17:27879388:C:A
Pancreas	eqtl	8.7e-42	-1.08	17:27879388:C:A
Brain Putamen basal ganglia	eqtl	8.2e-41	-0.90	17:27879388:C:A
Thyroid	eqtl	2.6e-40	-0.75	17:27879388:C:A
Brain Caudate basal ganglia	eqtl	1.5e-38	-0.85	17:27879388:C:A
Brain Hypothalamus	eqtl	1.6e-33	-0.94	17:27879388:C:A
Stomach	eqtl	1.2e-32	-0.78	17:27879388:C:A
Colon Sigmoid	eqtl	3.5e-31	-0.67	17:27879388:C:A
Artery Aorta	eqtl	4.2e-29	-0.70	17:27895494:G:A

FANTOM5 promoters

5 alternative TSS:

Promoter ID	TPM avg	Samples expressed
164964	8.5358	227
164961	0.1287	21
164960	0.0832	17
164965	0.0786	14
164962	0.0766	21

Top tissues by expression

showing 100 of 281 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	94.55	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	89.37	gold quality
mucosa of paranasal sinus	UBERON:0005030	83.14	silver quality
mucosa of transverse colon	UBERON:0004991	78.91	gold quality
rectum	UBERON:0001052	78.33	gold quality
vermiform appendix	UBERON:0001154	77.76	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	72.81	silver quality
caecum	UBERON:0001153	71.55	gold quality
prefrontal cortex	UBERON:0000451	69.81	gold quality
duodenum	UBERON:0002114	68.57	gold quality
right frontal lobe	UBERON:0002810	68.40	gold quality
nasal cavity mucosa	UBERON:0001826	68.37	gold quality
small intestine	UBERON:0002108	67.13	gold quality
small intestine Peyer’s patch	UBERON:0003454	67.03	gold quality
transverse colon	UBERON:0001157	66.91	gold quality
colonic epithelium	UBERON:0000397	65.38	silver quality
Brodmann (1909) area 9	UBERON:0013540	65.14	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	64.91	gold quality
frontal cortex	UBERON:0001870	64.53	gold quality
parotid gland	UBERON:0001831	64.02	gold quality
neocortex	UBERON:0001950	63.13	gold quality
Brodmann (1909) area 10	UBERON:0013541	62.90	gold quality
jejunal mucosa	UBERON:0000399	62.05	gold quality
frontal pole	UBERON:0002795	62.00	gold quality
intestine	UBERON:0000160	61.33	gold quality
ventricular zone	UBERON:0003053	60.66	gold quality
tendon of biceps brachii	UBERON:0008188	60.61	gold quality
cingulate cortex	UBERON:0003027	60.41	gold quality
endometrium epithelium	UBERON:0004811	60.31	gold quality
upper lobe of left lung	UBERON:0008952	60.28	gold quality
anterior cingulate cortex	UBERON:0009835	60.14	gold quality
buccal mucosa cell	CL:0002336	59.95	gold quality
large intestine	UBERON:0000059	59.83	gold quality
colon	UBERON:0001155	59.64	gold quality
cortical plate	UBERON:0005343	59.45	gold quality
cerebral cortex	UBERON:0000956	59.24	gold quality
right lung	UBERON:0002167	59.19	gold quality
ganglionic eminence	UBERON:0004023	58.88	gold quality
middle frontal gyrus	UBERON:0002702	58.82	gold quality
decidua	UBERON:0002450	58.66	gold quality
upper lobe of lung	UBERON:0008948	58.41	gold quality
smooth muscle tissue	UBERON:0001135	58.21	gold quality
paraflocculus	UBERON:0005351	58.14	gold quality
medial globus pallidus	UBERON:0002477	57.65	gold quality
lymph node	UBERON:0000029	56.72	gold quality
telencephalon	UBERON:0001893	56.42	gold quality
pancreatic ductal cell	CL:0002079	56.13	silver quality
forebrain	UBERON:0001890	55.86	gold quality
ileal mucosa	UBERON:0000331	55.78	gold quality
adult mammalian kidney	UBERON:0000082	55.43	gold quality
colonic mucosa	UBERON:0000317	55.39	gold quality
metanephros cortex	UBERON:0010533	55.19	gold quality
brain	UBERON:0000955	55.13	gold quality
adenohypophysis	UBERON:0002196	55.02	gold quality
central nervous system	UBERON:0001017	54.95	gold quality
amygdala	UBERON:0001876	54.83	gold quality
pituitary gland	UBERON:0000007	54.74	gold quality
cerebellar hemisphere	UBERON:0002245	54.61	gold quality
cerebellar cortex	UBERON:0002129	54.58	gold quality
embryo	UBERON:0000922	54.36	gold quality
right hemisphere of cerebellum	UBERON:0014890	54.28	gold quality
hindlimb stylopod muscle	UBERON:0004252	54.20	gold quality
mucosa of sigmoid colon	UBERON:0004993	54.06	gold quality
cerebellar vermis	UBERON:0004720	54.00	gold quality
globus pallidus	UBERON:0001875	53.91	gold quality
cerebellum	UBERON:0002037	53.90	gold quality
primary visual cortex	UBERON:0002436	53.70	gold quality
gall bladder	UBERON:0002110	53.49	gold quality
lung	UBERON:0002048	53.42	gold quality
muscle of leg	UBERON:0001383	53.21	gold quality
nucleus accumbens	UBERON:0001882	53.04	gold quality
tibial nerve	UBERON:0001323	53.00	gold quality
muscle organ	UBERON:0001630	52.52	gold quality
Brodmann (1909) area 46	UBERON:0006483	52.47	gold quality
hair follicle	UBERON:0002073	52.43	gold quality
jejunum	UBERON:0002115	52.19	gold quality
caudate nucleus	UBERON:0001873	52.09	gold quality
metanephros	UBERON:0000081	52.02	gold quality
hypothalamus	UBERON:0001898	51.97	gold quality
quadriceps femoris	UBERON:0001377	51.94	gold quality
deltoid	UBERON:0001476	51.93	gold quality
muscle tissue	UBERON:0002385	51.92	gold quality
gastrocnemius	UBERON:0001388	51.91	gold quality
putamen	UBERON:0001874	51.83	gold quality
cortex of kidney	UBERON:0001225	51.80	gold quality
thymus	UBERON:0002370	51.66	silver quality
sigmoid colon	UBERON:0001159	51.55	gold quality
kidney	UBERON:0002113	51.38	gold quality
tibial artery	UBERON:0007610	51.01	gold quality
popliteal artery	UBERON:0002250	50.93	gold quality
muscle layer of sigmoid colon	UBERON:0035805	50.89	gold quality
placenta	UBERON:0001987	50.85	gold quality
vastus lateralis	UBERON:0001379	50.84	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	50.58	silver quality
epithelial cell of pancreas	CL:0000083	50.53	gold quality
occipital lobe	UBERON:0002021	50.46	gold quality
left adrenal gland cortex	UBERON:0035825	50.45	gold quality
right coronary artery	UBERON:0001625	50.32	gold quality
skeletal muscle tissue	UBERON:0001134	50.27	gold quality
left adrenal gland	UBERON:0001234	50.05	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.03

HPA expression

RNA tissue specificity: Group enriched

showing 60 of 102 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Small intestine	tissue	19.6	not detected
Appendix	tissue	13.8	medium
Duodenum	tissue	11.0	low
Rectum	tissue	8.2	medium
Colon	tissue	6.3	medium
Urinary bladder	tissue	3.3	not detected
Cerebral cortex	tissue	2.1	low
Postcentral gyrus	tissue	2.1
Insular cortex	tissue	2.1
Testis	tissue	1.9	high
Prefrontal cortex	tissue	1.7
Basal ganglia	tissue	1.7	low
Retrosplenial and cingulate cortex	tissue	1.7
Smooth muscle	tissue	1.6	low
Motor cortex	tissue	1.6
Putamen	tissue	1.6
Hippocampal formation	tissue	1.6
Ventral forebrain	tissue	1.6
Retrosplenial cortex	tissue	1.6
Temporal cortex	tissue	1.6
Entorhinal cortex	tissue	1.5
Amygdala	tissue	1.4
Septum	tissue	1.4
Somatosensory cortex	tissue	1.4
Pituitary gland	tissue	1.3
Occipital cortex	tissue	1.3
Testis	tissue	1.2	not detected
Olfactory bulb	tissue	1.2
Hypothalamus	tissue	1.1
Lung	tissue	1.1	not detected
Corpus callosum	tissue	0.9
Spinal cord	tissue	0.8
Periaqueductal gray	tissue	0.8
Pons	tissue	0.7
Adipose tissue	tissue	0.7	not detected
Medulla oblongata	tissue	0.7
Superior colliculi	tissue	0.7
Lymph node	tissue	0.6	not detected
Skeletal muscle	tissue	0.6	low
Midbrain	tissue	0.6
Thalamus	tissue	0.6
Substantia nigra	tissue	0.6
Ovary	tissue	0.5	not detected
Tongue	tissue	0.5
Frontal cortex	tissue	0.5
Nucleus accumbens	tissue	0.4
Placenta	tissue	0.4	not detected
Cerebellum	tissue	0.4	not detected
Thyroid gland	tissue	0.3	not detected
Gallbladder	tissue	0.3	not detected
Kidney	tissue	0.3	low
Locus coeruleus	tissue	0.3
Hippocampus	tissue	0.3	not detected
Fallopian tube	tissue	0.3	not detected
Caudate putamen	tissue	0.3
Cerebral cortex	tissue	0.3	not detected
Motor cortex	tissue	0.3
Basal ganglia	tissue	0.3	not detected
Hippocampal formation	tissue	0.3
Postcentral gyrus	tissue	0.3

Brain sub-regions (HPA Brain Atlas): detected in 359; highest nTPM — Precentral gyrus (1.8), Precentral gyrus, middle (1.7), Postcentral gyrus, middle (1.6), Subiculum (1.6), Transversal temporal gyrus, anterior (1.4).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting NOS2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 55 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-609	99.82	64.26	505
HSA-MIR-34B-5P	99.78	67.56	1175
HSA-MIR-449C-5P	99.78	67.63	1168

Functional genomics

gnomAD constraint: pLI 2.06e-22, LOEUF 0.858, missense Z 2.17 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000313735 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
17:27,757,249–27,774,380	782 / 909.9	0.86	no
17:27,774,381–27,778,715	15 / 41.6	0.36	no
17:27,778,716–27,798,809	440 / 545.4	0.81	no

Literature-anchored findings (GeneRIF, showing 40)

• The specific NOS2 inhibitor, 1400W, sensitizes HepG2 cells to genotoxic, oxidative, xenobiotic, and endoplasmic reticulum stresses (PMID:11761338)
• Inos enzyme overexpressioin is an early event in esophageal carcinogenesis and useful biomarkers for early detection. (PMID:11783017)
• Human renal epithelial cells express iNOS in response to cytokines but not bacteria (PMID:11849384)
• The human alveolar type II epithelium-like cell line A549 expresses nitric oxide synthase type 2 (NOS2) (PMID:11880293)
• Immunohistochemical expression of iNOS in colorectal carcinoma (PMID:11956620)
• Increased expression of iNOS may be responsible for gastric carcinogenesis and tumor aggressiveness of gastric cancer and correlates significantly with lymph node metastasis in northern China. (PMID:11978184)
• demonstrated that the iNOS gene was actively transcribed in cutaneous leishmaniasis lesions (PMID:11985871)
• Inducible nitric oxide synthase is expressed in normal human melanocytes but not in melanoma cells (PMID:12060397)
• epithelial iNOS binds to EPB50 which directs vectorial nitric oxide output (PMID:12080081)
• allelic polymorphism of the inducible nitric oxide synthase (iNOS) gene associated with retinopathy in an Asian Indian population (PMID:12081717)
• enzyme expressed in septic patients is nitrated on selected tyrosine residues; implications for enzymic activity (PMID:12097137)
• expression of inducible nitric oxide synthase in skin lesions of patients with cutaneous leishmaniasis (PMID:12117977)
• Data show that prostacyclin receptor mediated increases in cAMP play a role in enhancing LPS/IFN-gamma-induced iNOS expression in human monocytes/macrophages and may contribute to the increased production of NO during peritonitis. (PMID:12119468)
• expression is increased in malaria, thus producing more nitric oxide (PMID:12125143)
• inducible nitric oxide synthase promoter polymorphism in rheumatoid arthritis (PMID:12140750)
• iNOS is induced by HIV-1 tat in astrocytes and may play a role in HIV-associated dementia (PMID:12167619)
• expressions of iNOS and VEGF may serve as indexes for evaluating staging of gastric carcinoma and forecasting its risk of metastasis (PMID:12174362)
• iNOS is subject to ubiquitination and ubiquitination is required for its degradation. (PMID:12221289)
• EGF protects against oxidative disruption of the intestinal barrier by stabilizing the cytoskeleton in large part through the activation of PKC-zeta and downregulation of iNOS (PMID:12223351)
• These results suggest that IL-15 is a potent regulator of iNOS expression by HGEC and involved in innate immunity in the mucosal epithelium. (PMID:12237122)
• Data demonstrate that the PI3-kinase signaling pathway is involved in basal trophoblast motility and that both mitogen-activated protein kinase and PI3-kinase signaling pathways are important in HGF-stimulated motility and iNOS expression. (PMID:12243747)
• Synovial fluid leucocytes, in particular granulocytes, express iNOS and may thus contribute to intra-articular NO production in arthritis. (PMID:12296866)
• iNOS may not correlate with cancer cell-proliferative activity or apoptosis (PMID:12374680)
• role of NF-kappa B-repressing factor (NRF) in basal repression of the hiNOS gene (PMID:12381793)
• strong upregulation of iNOS might contribute to inflammatory processes in fulminant hepatic failure (PMID:12399227)
• Activation might be associated with malignant potential of epithelial odontogenic tumors (PMID:12406306)
• Association analysis of five polymorphic microsatellite markers in cluster headache (CH) patients reveals that genetic variations in NOS2A do not contribute greatly to CH susceptibility. (PMID:12421162)
• hepatic inducible nitric oxide synthase staining was significantly more intense in patients with chronic viral hepatitis; these results suggest that inducible nitric oxide synthase may have a critical role in the pathogenesis of chronic viral hepatitis (PMID:12431203)
• NOS2 promoter -1173 C–>T single nucleotide polymorphism is associated with protection against cerebral malaria and severe malarial anaemia (PMID:12433515)
• Increased intrahepatic iNOS expression and nitrotyrosine accumulation in biliary cirrhosis and autoimmune hepatitis, related to histological severity of liver disease. (PMID:12445411)
• nitric oxide synthases(inducible, brain and endothelial) were expressed in human pregnant term uterus and did not change in the myometrium during labor (PMID:12445599)
• A positive correlation was found between the positive expression of iNOS mRNA and invasive growth as well as neck lymph node metastatsis of squamous cell carcinoma of tongue. (PMID:12452003)
• Data show that nitric oxide produced by inducible nitric oxide synthase (iNOS) increases the activity of cyclooxygenase-2 (COX-2) pathways in head and neck squamous cell carcinomas, and this effect is probably mediated by endocellular cGMP. (PMID:12459168)
• inducible nitric oxide synthase-cyclooxygenase 2 interactions are involved in tumor cell angiogenesis and migration (PMID:12462194)
• Upregulation of iNOS in myelodysplastic syndromes has no significant correlation with apoptosis. (PMID:12486325)
• Immunolocalization of inducible nitric oxide synthase in gingiva in localized juvenile periodontitis patients. iNOS in gingivitis. Macrophages expressed high levels of iNOS. (PMID:12489192)
• Altered genetic control of NOS2 transcription may be a risk factor for SLE among African-American females. (PMID:12508391)
• study demonstrate that expression of the MDA-7 tumor suppressor can negatively regulate iNOS expression in malignant melanoma cell lines (PMID:12533668)
• A single haplotype, uniquely defined by the NOS2A-1659T allele, was associated with cerebral malaria by a transmission disequilibrium . (PMID:12552317)
• upregulation of hepatic iNOS, associated with peroxisomal localization, is an early molecular early molecular response to hemorrhagic shock (PMID:12578118)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	nos2a	ENSDARG00000026925
danio_rerio	nos2b	ENSDARG00000031976
mus_musculus	Nos2	ENSMUSG00000020826
rattus_norvegicus	Nos2	ENSRNOG00000057443
rattus_norvegicus	Nos2-ps1	ENSRNOG00000078225

Paralogs (5): NOS1 (ENSG00000089250), MTRR (ENSG00000124275), POR (ENSG00000127948), NOS3 (ENSG00000164867), NDOR1 (ENSG00000188566)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:97361) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 153 distinct phenotype terms.

Mouse phenotype (MP)	Records
hyperglycemia	3
abnormal glucose homeostasis	3
increased circulating creatinine level	3
increased body weight	2
increased circulating triglyceride level	2
decreased inflammatory response	2
increased susceptibility to bacterial infection	2
abnormal osteoclast morphology	2
abnormal heart ventricle morphology	2
increased T cell proliferation	2
increased interferon-gamma secretion	2
decreased susceptibility to endotoxin shock	2
abnormal blood homeostasis	2
abnormal trabecular bone morphology	1
abnormal circulating glucose level	1
abnormal circulating serum albumin level	1
abnormal systemic arterial blood pressure	1
abnormal heart morphology	1
decreased digestive secretion	1
abnormal immune system morphology	1
abnormal corpus callosum morphology	1
abnormal uterus morphology	1
abnormal testis morphology	1
abnormal eating behavior	1
abnormal sleep pattern	1

+128 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Escherichia coli APEC O1	A1AEV0	100.0%	Diamond
Yersinia pestis Pestoides F	A4TPY5	100.0%	Diamond
Escherichia coli O139:H28 str. E24377A	A7ZQK7	100.0%	Diamond
Escherichia coli ATCC 8739	B1IU77	100.0%	Diamond
Staphylococcus aureus	P0A004	100.0%	Diamond
Staphylococcus aureus subsp. aureus Mu50	P0A092	100.0%	Diamond
Staphylococcus aureus subsp. aureus N315	P0A093	100.0%	Diamond
Staphylococcus aureus subsp. aureus MW2	P0A094	100.0%	Diamond
Shigella flexneri 5 str. 8401	Q0T1I8	100.0%	Diamond
Escherichia coli 536	Q0TEA2	100.0%	Diamond
Yersinia pestis Antiqua	Q1C3Z0	100.0%	Diamond
Yersinia pestis Nepal516	Q1CLS8	100.0%	Diamond
Escherichia coli UTI89	Q1R7T4	100.0%	Diamond
Staphylococcus aureus subsp. aureus COL	Q5HEK7	100.0%	Diamond
Staphylococcus aureus subsp. aureus MSSA476	Q6G818	100.0%	Diamond
Shigella flexneri	Q83QD9	100.0%	Diamond
Yersinia pestis	Q8ZBN6	100.0%	Diamond
Escherichia coli K-12	P38038	99.8%	Diamond
Shigella boydii Sb227	Q31XM4	99.8%	Diamond
Escherichia coli CFT073	Q8FEI7	99.8%	Diamond
Vibrio cholerae O395	A5F3I4	99.7%	Diamond
Yersinia pseudotuberculosis IP 31758	A7FLZ0	99.7%	Diamond
Shigella sonnei Ss046	Q3YY94	99.7%	Diamond
Vibrio cholerae O1 biovar El Tor str. N16961	Q9KUX4	99.7%	Diamond
Escherichia coli HS	A8A3P5	99.3%	Diamond
Escherichia coli O157:H7	Q8X7U1	99.3%	Diamond
Shigella dysenteriae Sd197	Q32CG3	99.0%	Diamond
Yersinia pseudotuberculosis IP 32953	Q66ED4	98.9%	Diamond
Staphylococcus aureus subsp. aureus MRSA252	Q6GFE2	98.6%	Diamond
Salmonella enterica subsp. enterica serovar Paratyphi B str. SPB7	A9N2E6	98.5%	Diamond
Salmonella enterica subsp. enterica serovar Typhimurium str. LT2	P38039	98.5%	Diamond
Shewanella sp. MR-4	Q0HFL6	98.5%	Diamond
Shewanella sp. MR-7	Q0HYB4	98.5%	Diamond
Neisseria meningitidis 053442	A9LZ73	98.3%	Diamond
Neisseria meningitidis Z2491	Q9JUD8	98.3%	Diamond
Shewanella sp. ANA-3	A0KTH4	98.2%	Diamond
Neisseria meningitidis FAM18	A1KU06	98.0%	Diamond
Salmonella enterica subsp. enterica serovar Paratyphi A str. ATCC 9150	Q5PEH7	97.8%	Diamond
Salmonella enterica subsp. enterica serovar Typhi	Q8Z458	97.8%	Diamond
Bos taurus	Q27995	97.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
LYRM9	protein-coding	201229
LINC01992	ncRNA	105371708

Protein

Protein identifiers

Nitric oxide synthase, inducible — P35228 (reviewed: P35228)

Alternative names: Hepatocyte NOS, Inducible NO synthase, NOS type II, Peptidyl-cysteine S-nitrosylase NOS2

All UniProt accessions (6): P35228, A0A2R8YDS4, A0A8V8TKX9, A0A8V8TKZ7, A0A8V8TLB1, A0A8V8TMI7

UniProt curated annotations — full annotation on UniProt →

Function. Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity and mediates cysteine S-nitrosylation of cytoplasmic target proteins such PTGS2/COX2. As component of the iNOS-S100A8/9 transnitrosylase complex involved in the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on ‘Cys-247’ implicated in regulation of the GAIT complex activity and probably multiple targets including ANXA5, EZR, MSN and VIM. Involved in inflammation, enhances the synthesis of pro-inflammatory mediators such as IL6 and IL8.

Subunit / interactions. Homodimer. Interacts with NHERF1. Interacts with GAPDH; induced by oxidatively-modified low-densitity lipoprotein (LDL(ox)). Interacts with S100A8 and S100A9 to form the iNOS-S100A8/9 transnitrosylase complex. Interacts with SPSB1, SPSB2 and SPSB4. Interacts with ELOC and CUL5 in the presence of SPSB1 or SPSB2 or SPSB4. Forms a complex with ASL, ASS1 and HSP90AA1; the complex regulates cell-autonomous L-arginine synthesis and citrulline recycling while channeling extracellular L-arginine to nitric oxide synthesis pathway.

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Expressed in the liver, retina, bone cells and airway epithelial cells of the lung. Not expressed in the platelets. Expressed in chondrocytes.

Post-translational modifications. Polyubiquitinated; mediated by SPSB1, SPSB2 and SPSB4, leading to proteasomal degradation.

Activity regulation. Regulated by calcium/calmodulin. Aspirin inhibits expression and function of this enzyme and effects may be exerted at the level of translational/post-translational modification and directly on the catalytic activity.

Cofactor. Binds 1 FAD. Binds 1 FMN. Tetrahydrobiopterin (BH4). May stabilize the dimeric form of the enzyme.

Induction. By endotoxins and cytokines. Induced by IFNG/IFN-gamma acting synergistically with bacterial lipopolysaccharides (LPS), TNF or IL1B/interleukin-1 beta. Down-regulated by zinc due to inhibition of NF-kappa-B transactivation activity. By oxidatively-modified low-densitity lipoprotein (LDL(ox)).

Polymorphism. Genetic variations in NOS2 are involved in resistance to malaria [MIM:611162].

Similarity. Belongs to the NOS family.

Isoforms (2)

UniProt ID	Names	Canonical?
P35228-1	1	yes
P35228-2	2

RefSeq proteins (1): NP_000616* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001094	Flavdoxin-like	Domain
IPR001433	OxRdtase_FAD/NAD-bd	Domain
IPR001709	Flavoprot_Pyr_Nucl_cyt_Rdtase	Domain
IPR003097	CysJ-like_FAD-binding	Domain
IPR004030	NOS_N	Domain
IPR008254	Flavodoxin/NO_synth	Domain
IPR012144	NOS_euk	Family
IPR017927	FAD-bd_FR_type	Domain
IPR017938	Riboflavin_synthase-like_b-brl	Homologous_superfamily
IPR023173	NADPH_Cyt_P450_Rdtase_alpha	Homologous_superfamily
IPR029039	Flavoprotein-like_sf	Homologous_superfamily
IPR036119	NOS_N_sf	Homologous_superfamily
IPR039261	FNR_nucleotide-bd	Homologous_superfamily
IPR044940	NOS_dom_2	Homologous_superfamily
IPR044943	NOS_dom_1	Homologous_superfamily
IPR044944	NOS_dom_3	Homologous_superfamily
IPR050607	NOS	Family

Pfam: PF00175, PF00258, PF00667, PF02898

Enzyme classification (BRENDA)

• EC 1.14.13.39 — nitric-oxide synthase (NADPH) (BRENDA: 31 organisms, 140 substrates, 179 inhibitors, 88 Km, 25 kcat entries)

Substrate kinetics (BRENDA)

11 substrates with measured Km, best-characterized 11. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
L-ARGININE	0.0019–68.5	28
NADPH	0.0003–0.0041	9
TETRAHYDROBIOPTERIN	—	6
ADRIAMYCIN	0.012–0.078	5
MENADIONE	0.01–0.041	5
MITOMYCIN C	0.0073–0.055	5
NGAMMA-HYDROXY-L-ARGININE	0.019–0.129	5
2’,3’-DIALDEHYDE-NADPH	0.0008	1
CALMODULIN	—	1
NITROBLUE TETRAZOLIUM	0.016	1
NITRIC OXIDE	—	0

Catalyzed reactions (Rhea)

• 2 L-arginine + 3 NADPH + 4 O2 + H(+) = 2 L-citrulline + 2 nitric oxide + 3 NADP(+) + 4 H2O (RHEA:19897)

UniProt features (143 total): binding site 45, helix 36, strand 26, sequence conflict 15, sequence variant 5, turn 4, modified residue 4, domain 2, splice variant 2, chain 1, region of interest 1, short sequence motif 1, mutagenesis site 1

Structure

Experimental structures (PDB)

13 structures by resolution:

PDB	Title	Method	Resolution (Å)
6JWM	Crystal structure of the SPRY domain of SPSB2 in complex with cR7, a potent cyclic …	X-RAY DIFFRACTION	1.23
6KEY	Structural basis for the regulation of inducible nitric oxide synthase (iNOS) by the SPRY …	X-RAY DIFFRACTION	1.24
5XN3	Crystal structure of SPSB2 in complex with a rational designed RGD containing cyclic …	X-RAY DIFFRACTION	1.34
6JWN	Crystal structure of the SPRY domain of SPSB2 in complex with cR9, a cyclic peptide …	X-RAY DIFFRACTION	1.61
3E7G	Structure of human INOSOX with inhibitor AR-C95791	X-RAY DIFFRACTION	2.2
4NOS	HUMAN INDUCIBLE NITRIC OXIDE SYNTHASE WITH INHIBITOR	X-RAY DIFFRACTION	2.25
3HR4	Human iNOS Reductase and Calmodulin Complex	X-RAY DIFFRACTION	2.5
1NSI	HUMAN INDUCIBLE NITRIC OXIDE SYNTHASE, ZN-BOUND, L-ARG COMPLEX	X-RAY DIFFRACTION	2.55
3EJ8	Structure of double mutant of human iNOS oxygenase domain with bound immidazole	X-RAY DIFFRACTION	2.55
2NSI	HUMAN INDUCIBLE NITRIC OXIDE SYNTHASE, ZN-FREE, SEITU COMPLEX	X-RAY DIFFRACTION	3
4CX7	Structure of human iNOS heme domain in complex with (R)-6-(3-AMINO-2-(5-(2-(6-AMINO-4- …	X-RAY DIFFRACTION	3.16
2LL6	Solution NMR structure of CaM bound to iNOS CaM binding domain peptide	SOLUTION NMR
5TP6	Solution structure of the CaM34 with the iNOS CaM binding domain peptide	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P35228-F1	85.66	0.66

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Oxidoreductases, Metabolic proteins, Predicted intracellular proteins, Plasma proteins, Cancer-related genes, Candidate cancer biomarkers, FDA approved drug targets, Small molecule drugs, Human disease related genes

Protein evidence: Evidence at protein level

Antibody reliability (HPA): IH enhanced

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (45)

Position	Role
372	L-arginine
373	L-arginine
377	L-arginine
381	(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
462	(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
463	(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
476	(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
491	heme b
545	FMN
546	FMN
547	FMN
549	FMN
550	FMN
591	FMN
592	FMN
628	FMN
633	FMN
635	FMN
661	FMN
665	FMN
750	NADP(+)
772	FAD
906	FAD
908	FAD
909	FAD
924	FAD
926	FAD
929	NADP(+)
930	FAD
943	FAD
944	FAD
945	FAD
984	NADP(+)
1017	NADP(+)
1046	NADP(+)
1047	NADP(+)
1053	NADP(+)
1055	NADP(+)
1057	NADP(+)
1090	NADP(+)
110	Zn(2+)
115	Zn(2+)
118	(6R)-L-erythro-5,6,7,8-tetrahydrobiopterin
200	heme b
263	L-arginine

Post-translational modifications (4)

Type	Positions
Phosphoserine	234, 578, 892
Phosphotyrosine	575

Mutagenesis-validated functional residues (1)

Position	Phenotype
27	loss of interaction with spsb1 and spsb4.

Function

Pathways and Gene Ontology

Reactome pathways

4 curated (TAS) of 18; 7 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

18 pathways:

ID	Pathway	Evidence
R-HSA-9636249	Inhibition of nitric oxide production ⚕	curated
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	curated
R-HSA-392154	Nitric oxide stimulates guanylate cyclase	curated
R-HSA-1222556	ROS and RNS production in phagocytes	curated
R-HSA-9824439	Bacterial Infection Pathways ⚕	—
R-HSA-1643685	Disease ⚕	—
R-HSA-9635486	Infection with Mycobacterium tuberculosis ⚕	—
R-HSA-5663205	Infectious disease ⚕	—
R-HSA-9637690	Response of Mtb to phagocytosis ⚕	—
R-HSA-9637687	Suppression of phagosomal maturation ⚕	—
R-HSA-1280215	Cytokine Signaling in Immune system	—
R-HSA-109582	Hemostasis	—
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—
R-HSA-9033241	Peroxisomal protein import	electronic
R-HSA-418346	Platelet homeostasis	—
R-HSA-9609507	Protein localization	—
R-HSA-449147	Signaling by Interleukins	—

MSigDB gene sets: 351 (showing top): GOBP_CIRCADIAN_RHYTHM, LEE_NEURAL_CREST_STEM_CELL_DN, MORF_FLT1, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_REGULATION_OF_BLOOD_PRESSURE, MORF_MSH3, GOBP_CIRCULATORY_SYSTEM_PROCESS, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_POSITIVE_REGULATION_OF_INTERLEUKIN_8_PRODUCTION, GOBP_RESPONSE_TO_PEPTIDE, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS

GO Biological Process (24): positive regulation of leukocyte mediated cytotoxicity (GO:0001912), innate immune response in mucosa (GO:0002227), L-arginine catabolic process (GO:0006527), superoxide metabolic process (GO:0006801), nitric oxide biosynthetic process (GO:0006809), inflammatory response (GO:0006954), circadian rhythm (GO:0007623), response to bacterium (GO:0009617), response to hormone (GO:0009725), negative regulation of gene expression (GO:0010629), peptidyl-cysteine S-nitrosylation (GO:0018119), prostaglandin secretion (GO:0032310), response to lipopolysaccharide (GO:0032496), positive regulation of interleukin-6 production (GO:0032755), positive regulation of interleukin-8 production (GO:0032757), Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096), negative regulation of protein catabolic process (GO:0042177), defense response to bacterium (GO:0042742), regulation of cellular respiration (GO:0043457), cell redox homeostasis (GO:0045454), negative regulation of blood pressure (GO:0045776), regulation of insulin secretion (GO:0050796), defense response to Gram-negative bacterium (GO:0050829), regulation of cytokine production involved in inflammatory response (GO:1900015)

GO Molecular Function (12): nitric-oxide synthase activity (GO:0004517), calmodulin binding (GO:0005516), FMN binding (GO:0010181), heme binding (GO:0020037), tetrahydrobiopterin binding (GO:0034617), arginine binding (GO:0034618), protein homodimerization activity (GO:0042803), metal ion binding (GO:0046872), flavin adenine dinucleotide binding (GO:0050660), NADP binding (GO:0050661), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (9): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), peroxisome (GO:0005777), peroxisomal matrix (GO:0005782), cytosol (GO:0005829), plasma membrane (GO:0005886), cortical cytoskeleton (GO:0030863), perinuclear region of cytoplasm (GO:0048471)

Reactome top-level categories

13 top-level categories:

Category	Pathways
Immune System	2
Innate Immune System	1
Platelet homeostasis	1
Signaling by Interleukins	1
Protein localization	1
Suppression of phagosomal maturation	1
Hemostasis	1
Cytokine Signaling in Immune system	1
Disease	1
Bacterial Infection Pathways	1
Response of Mtb to phagocytosis	1
Infection with Mycobacterium tuberculosis	1
Infectious disease	1

GO top-level categories

showing 60 of 70 GO namespaces:

Category	Terms
cellular anatomical structure	4
defense response	2
positive regulation of cytokine production	2
anion binding	2
binding	2
cation binding	2
cytoplasm	2
leukocyte mediated cytotoxicity	1
regulation of leukocyte mediated cytotoxicity	1
positive regulation of leukocyte mediated immunity	1
positive regulation of cell killing	1
mucosal immune response	1
innate immune response	1
arginine metabolic process	1
amino acid catabolic process	1
proteinogenic amino acid catabolic process	1
reactive oxygen species metabolic process	1
biosynthetic process	1
nitric oxide metabolic process	1
rhythmic process	1
response to other organism	1
response to endogenous stimulus	1
response to chemical	1
gene expression	1
regulation of gene expression	1
negative regulation of macromolecule biosynthetic process	1
protein nitrosylation	1
prostaglandin transport	1
signal release	1
icosanoid secretion	1
lipid export from cell	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
interleukin-6 production	1
regulation of interleukin-6 production	1
interleukin-8 production	1
regulation of interleukin-8 production	1
Fc receptor mediated stimulatory signaling pathway	1
phagocytosis	1
Fc-gamma receptor signaling pathway	1
negative regulation of catabolic process	1
protein catabolic process	1
regulation of protein catabolic process	1
negative regulation of protein metabolic process	1
response to bacterium	1
regulation of generation of precursor metabolites and energy	1
cellular respiration	1
cellular homeostasis	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	1
protein binding	1
ribonucleotide binding	1
tetrapyrrole binding	1
amino acid binding	1
carboxylic acid binding	1
identical protein binding	1
protein dimerization activity	1
nucleotide binding	1
adenyl nucleotide binding	1
catalytic activity	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 14 of 46 annotations. The rest are phylogenetic / computational / electronic (IEA).

14 experimentally-supported GO terms:

GO term	NS	Evidence
Fc-gamma receptor signaling pathway involved in phagocytosis	BP	mutant phenotype
L-arginine catabolic process	BP	direct assay
defense response to bacterium	BP	mutant phenotype
negative regulation of gene expression	BP	genetic interaction
nitric oxide biosynthetic process	BP	direct assay
positive regulation of interleukin-6 production	BP	direct assay
positive regulation of interleukin-8 production	BP	direct assay
prostaglandin secretion	BP	direct assay
regulation of cytokine production involved in inflammatory response	BP	direct assay
regulation of insulin secretion	BP	mutant phenotype
cytoplasm	CC	direct assay
cytosol	CC	mutant phenotype
peroxisome	CC	direct assay
nitric-oxide synthase activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 2,454 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NOS2	IL1B	P01584	867
NOS2	PTGS2	P35354	857
NOS2	IFNG	P01579	848
NOS2	TNF	P01375	848
NOS2	ARG1	P05089	814
NOS2	IL6	P05231	802
NOS2	TLR4	O00206	743
NOS2	IL10	P22301	743
NOS2	NFKB1	P19838	692
NOS2	ARG2	P78540	679
NOS2	IL4	P05112	671
NOS2	TLR2	O60603	670
NOS2	IL1A	P01583	660
NOS2	MRC1	P22897	648
NOS2	EDN1	P05305	644

IntAct

Human interaction partners of NOS2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

4 partners by confidence:

Partner	Interaction type	MIscore	Records
GAPDH	physical association	0.500	7
S100A8	association	0.460	2
ADRM1	physical association	0.400	1
UCHL5	physical association	0.400	1

BioGRID (224 interactions; top human partners by supporting records): SPSB2 (Biochemical Activity; 13 records), SPSB1 (Affinity Capture-Western; 7 records), CALM1 (Reconstituted Complex; 5 records), FBXO45 (Affinity Capture-MS; 3 records), HSP90AA1 (Affinity Capture-MS; 3 records), RAC2 (Affinity Capture-Western; 3 records), SPSB4 (Affinity Capture-Western; 3 records), CAV1 (Co-fractionation; 2 records), CUL5 (Affinity Capture-Western; 2 records), TCEB1 (Affinity Capture-Western; 2 records), UCHL5 (Affinity Capture-Western; 2 records), ACAA1 (FRET), AGR2 (Affinity Capture-MS), AIFM1 (Affinity Capture-MS), AKR1B10 (Affinity Capture-MS)

SIGNOR signaling

9 signaling interactions:

A	Effect	B	Mechanism
PRKAA1	down-regulates	NOS2
MAPK3	up-regulates	NOS2	phosphorylation
SRC	up-regulates	NOS2	phosphorylation
STAT1	“up-regulates quantity by expression”	NOS2	“transcriptional regulation”
NfKb-p65/p50	“up-regulates quantity by expression”	NOS2	“transcriptional regulation”
NOS2	up-regulates	“nitric oxide”
NOS2	up-regulates	L-citrulline
L-arginine	up-regulates	NOS2
NfKb-p65/p50	up-regulates	NOS2	“transcriptional regulation”

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
iNOS-S100A8/A9 complex	3	S100A8, S100A9, NOS2

Disease & clinical

Genetic variants

Variant evidence for NOS2: 213 ClinVar records (0 pathogenic / likely pathogenic).

ClinVar

213 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	143
Likely benign	40
Benign	20

AlphaMissense

2,099 missense substitutions predicted likely pathogenic (of 7,616 scored), across 553 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M223	9	0.820	0.979
F369	8	0.976	0.997
D435	8	0.966	0.989
F247	8	0.959	0.992
D98	8	0.954	0.987
D280	8	0.953	0.984
H230	8	0.947	0.987
D412	8	0.947	0.985
F443	8	0.941	0.993
D460	8	0.936	0.986
H436	8	0.933	0.986
H333	8	0.910	0.987
D385	8	0.909	0.962
N196	8	0.908	0.994
F339	8	0.908	0.990
H437	8	0.904	0.985
F1128	8	0.903	0.989
N261	8	0.900	0.995
F565	8	0.899	0.981
D833	8	0.899	0.961

HPA cancer prognostics

RNA cancer specificity: Group enriched (Colon Adenocarcinoma, Glioblastoma Multiforme, Lung Squamous Cell Carcinoma, Rectum Adenocarcinoma, Stomach Adenocarcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	2.97e-06
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000338

Disease associations

OMIM: gene MIM:163730 | disease phenotypes:

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
schizophrenia	No Known Disease Relationship	Unknown

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (1 panels, 1 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

1 panels:

Panel	Rating
COVID-19 research	green

Mondo (1): schizophrenia (MONDO:0005090)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2096621 (SELECTIVITY GROUP), CHEMBL2111350 (SELECTIVITY GROUP), CHEMBL4481 (SINGLE PROTEIN), CHEMBL4630725 (PROTEIN FAMILY)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the NOS2 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

2 curated-mechanism drugs:

Drug	Modality	Max phase
GW-274150	Small molecule	2
KD7040	Small molecule	2

Drugs acting on a complex or family that includes this protein

Curated ChEMBL mechanism-of-action drugs whose target is a protein complex or family of ≤10 members that includes NOS2 — the drug acts on the assembly or class, not necessarily on this subunit alone.

1 drugs via a complex or family:

Drug	Target (ChEMBL)	Members	Max phase
TILARGININE	Nitric oxide synthase	3	3

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,049,502 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

10 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1371	CHLORZOXAZONE	4	16,875
CHEMBL1485	ARGININE	3	905,111
CHEMBL140	CURCUMIN	3	95,185
CHEMBL256147	TILARGININE	3	2,046
CHEMBL114551	GW-274150	2	1,071
CHEMBL1911882	KD7040	2	8
CHEMBL1093059	BARDOXOLONE	2	944
CHEMBL7890	L-NAME	2	1,196
CHEMBL225304	PIMAGEDINE	2	24,594
CHEMBL227744	NITROARGININE	1	2,472

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Nitric oxide synthases

Most potent curated ligand interactions (7 total), top 7:

Ligand	Action	Affinity	Parameter
1400W	Inhibition	8.2	pIC50
2-amino-4-methylpyridine	Inhibition	7.4	pIC50
PIBTU	Inhibition	7.3	pIC50
GW274150	Inhibition	7.15	pIC50
L-NNA	Inhibition	6.17	pKi
tilarginine	Inhibition	6.07	pKi
NIL	Inhibition	5.5	pIC50

Binding affinities (BindingDB)

953 measured of 1094 human assays (1178 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
2-((R)-1-(2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl)pyrrolidin-2-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl)acetamide	IC50	0.12 nM
2-((R)-1-(2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl)pyrrolidin-2-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl)acetamide	IC50	0.13 nM
methyl (3S)-3-{2-[(1,3-benzodioxol-5-ylmethyl)amino]-2-oxoethyl}-4-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]piperazine-1-carboxylate	IC50	0.24 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(6-fluoropyridin-2-yl)-2-piperazineacetamide	IC50	0.28 nM
2-((R)-1-(2-(1H-imidazol-1-yl)pyrimidin-4-yl)pyrrolidin-2-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl)acetamide	IC50	0.28 nM
N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE	IC50	0.29 nM
3-{[(Benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-methyl}-4-(2-imidazol-1-yl-pyrimidin-4-yl)-piperazine-1-carboxylic acid methyl ester	IC50	0.38 nM
2-((R)-1-(2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl)pyrrolidin-2-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl)acetamide	IC50	0.48 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-methyl-2-piperazineacetamide	IC50	0.48 nM
N-(1,3-benzodioxol-5-ylmethyl)-1-[6-chloro-2-(1H-imidazol-1-yl)-4-pyrimidinyl]-2-piperidineacetamide	IC50	0.49 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(methylsulfonyl)-2-piperazineacetamide	IC50	0.5 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)-4-pyrimidinyl]-2-piperidineacetamide	IC50	0.5 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(phenylcarbonyl)-2-piperazineacetamide	IC50	0.5 nM
N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-4-pyrimidinyl]-3-morpholineacetamide	IC50	0.5 nM
(2R)-N-(2-(benzo[d][1,3]dioxol-5-yl)ethyl)-1-(6-ethyl-2-(1H-imidazol-1-yl)pyrimidin-4-yl)pyrrolidine-2-carboxamide	IC50	0.52 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-2-piperazineacetamide	IC50	0.55 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(2-furylmethyl)-2-piperazineacetamide	IC50	0.58 nM
N-(1,3-benzodioxol-5-ylmethyl)-4-(2-furanylcarbonyl)-1-[2-(1H-imidazolyl)-4-pyrimidinyl]-2-piperazineacetamide	IC50	0.67 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(methylsulfonyl)-2-piperazineacetamide	IC50	0.7 nM
2-((R)-4-(2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl)-1-isobutyrylpiperazin-2-yl)-N-(benzo[d][1,3]dioxol-5-ylmethyl)acetamide	IC50	0.75 nM
1-[2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N-[(4-methoxyphenyl-)methyl]-2-piperidineacetamide	IC50	0.8 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-[(phenylmethoxy)carbonyl]piperazine-2-acetamide	IC50	0.8 nM
N-(1,3-benzodioxol-5-ylmethyl)-1-[2-(1H-imidazol-yl)-4-pyrimidinyl]-4-(phenylamino)carbonyl]-2-piperazineacetamide	IC50	0.87 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(2-furylmethyl)-2-piperazineacetamide	IC50	0.93 nM
N-(1,3-benzodioxol-5-ylmethyl)-1-[2-(1H-imidazol-yl)-4-pyrimidinyl]-4-[[(phenylmethyl)amino]carbonyl]-2-piperazineacetamide	IC50	0.96 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(phenylmethyl)-2-piperazineacetamide	IC50	1 nM
3-[2-[(1,3-benzodioxol-5-ylmethyl)amino]-2-oxoethyl]-4-[2-(1H-imidazolyl)-4-pyrimidinyl]-1-piperazinecarboxylic Acid, 1-methyl ethyl ester	IC50	1 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-[(methylamino)carbonyl]-2-piperazineacetamide	IC50	1 nM
4-(acetyl)-N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-2-piperazineacetamide	IC50	1 nM
N-[(1,3-benzodioxol-5-yl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-4-(3-methylbutyl)-2-piperazineacetamide	IC50	1 nM
CHEMBL106871	IC50	1 nM
N-Benzo[1,3]dioxol-5-ylmethyl-2-[1-(6-chloro-2-imidazol-1-yl-pyrimidin-4-yl)-piperazin-2-yl]-acetamide	IC50	1.1 nM
N-[(1,3-benzodioxol-5-yl)methyl]-4-[(5-dimethylaminonaphthyl)sulfonyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-2-piperazineacetamide	IC50	1.1 nM
3-[2-[(1,3-benzodioxol-5-ylmethyl)amino]-2-oxoethyl]-4-[2-(1H-imidazolyl)-4-pyrimidinyl]-1-piperazinecarboxylic acid, phenyl ester	IC50	1.4 nM
1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3,4-dimethoxyphenyl)methyl]-2-piperidineacetamide	IC50	1.5 nM
N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-1-[(1-methylethyl)carbonyl]-2-piperazineacetamide	IC50	1.9 nM
8a-(imidazole-1-carbonyl)-4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-4a,5,6,6a,7,8,9,10,12,12a-decahydropicene-2-carbonitrile	IC50	2 nM	US-10189791: Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
N-[(1,3-benzodioxol-5-yl)methyl]hexahydro-1-[2-(1H-imidazol-1-yl)-4-pyrimidinyl]-1H-azepine-2-acetamide	IC50	2 nM
N-(1,3-benzodioxol-5-ylmethyl)-1-[2-(1H-imidazol-yl)-4-pyrimidinyl]-4-(phenylsulfonyl)-2-piperazineacetamide	IC50	2.7 nM
N-[(4-fluorophenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-2-piperidineacetamide	IC50	3 nM
1-[2-(1H-imidazol-1-yl)-4-pyrimidinyl]-N-[2-(4-methoxyphenyl)ethyl]-2-piperidineacetamide	IC50	3.5 nM
1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-N-[(3-methoxyphenyl-)methyl]-2-piperidineacetamide	IC50	3.7 nM
N-(1,3-benzodioxol-5-ylmethyl)-1-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-2-piperidineacetamide	IC50	4.1 nM
4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-8a-(4-pyridin-3-ylimidazole-1-carbonyl)-4a,5,6,6a,7,8,9,10,12,12a-decahydropicene-2-carbonitrile	IC50	4.3 nM	US-10189791: Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
2-[2-[(1,3-benzodioxol-5-ylmethyl)amino]-2-oxoethyl]-4-[2-(1H-imidazol-1-yl)-6-methyl-4-pyrimidinyl]-1-piperazinecarboxylic acid, methyl ester	IC50	5.4 nM
N-[(4-chlorophenyl)methyl]-1-[2-(1H-imidazol-1-yl)pyrimidin-4-yl]-2-piperidineacetamide	IC50	5.7 nM
4,4,6a,6b,11,11,14b-heptamethyl-3,13-dioxo-8a-(4-pyridin-2-ylimidazole-1-carbonyl)-4a,5,6,6a,7,8,9,10,12,12a-decahydropicene-2-carbonitrile	IC50	5.8 nM	US-10189791: Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
N-(3-Aminomethyl-phenyl)-furan-2-carboxamidine	KI	6 nM
N-(3-Aminomethyl-phenyl)-furan-2-carboxamidine	KI	6.3 nM
N-[(1,3-benzodioxol-5-yl)methyl]-4-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-1-(methylcarbonyl)-2-piperazineacetamide	IC50	8.5 nM

ChEMBL bioactivities

966 potent at pChembl≥5 of 1253 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.92	IC50	0.12	nM	CHEMBL220632
9.89	IC50	0.13	nM	CHEMBL220880
9.70	IC50	0.2	nM	BARDOXOLONE
9.62	IC50	0.24	nM	CHEMBL385324
9.55	IC50	0.28	nM	CHEMBL385325
9.55	IC50	0.28	nM	CHEMBL376733
9.54	IC50	0.29	nM	CHEMBL376632
9.42	IC50	0.38	nM	CHEMBL290548
9.32	IC50	0.48	nM	CHEMBL373623
9.32	IC50	0.48	nM	CHEMBL427062
9.31	IC50	0.49	nM	CHEMBL223788
9.30	IC50	0.5	nM	CHEMBL376713
9.30	IC50	0.5	nM	CHEMBL385334
9.30	IC50	0.5	nM	CHEMBL220932
9.30	IC50	0.5	nM	CHEMBL442041
9.28	IC50	0.52	nM	CHEMBL221208
9.26	IC50	0.55	nM	CHEMBL411343
9.24	IC50	0.58	nM	CHEMBL424928
9.22	IC50	0.6	nM	CHEMBL290548
9.17	IC50	0.67	nM	CHEMBL223782
9.15	IC50	0.7	nM	CHEMBL373881
9.12	IC50	0.75	nM	CHEMBL222362
9.10	IC50	0.8	nM	CHEMBL223792
9.10	IC50	0.8	nM	CHEMBL374681
9.06	IC50	0.87	nM	CHEMBL374319
9.03	IC50	0.93	nM	CHEMBL222364
9.02	IC50	0.96	nM	CHEMBL223791
9.00	IC50	1	nM	CHEMBL374132
9.00	IC50	1	nM	CHEMBL220834
9.00	IC50	1	nM	CHEMBL375404
9.00	IC50	1	nM	CHEMBL223384
9.00	IC50	1	nM	CHEMBL223634
8.96	IC50	1.1	nM	CHEMBL440473
8.96	IC50	1.1	nM	CHEMBL223838
8.85	IC50	1.4	nM	CHEMBL223385
8.82	IC50	1.5	nM	CHEMBL220121
8.74	Ki	1.8	nM	CHEMBL1800346
8.74	IC50	1.8	nM	TILARGININE
8.73	Ki	1.862	nM	CHEMBL1800346
8.72	IC50	1.9	nM	CHEMBL220771
8.70	IC50	2	nM	CHEMBL223442
8.70	EC50	2	nM	CHEMBL489724
8.70	Ki	2	nM	CHEMBL105792
8.70	IC50	2	nM	CHEMBL5947337
8.70	IC50	2	nM	CHEMBL354788
8.66	Ki	2.2	nM	CHEMBL290548
8.57	IC50	2.7	nM	CHEMBL220156
8.52	IC50	3	nM	CHEMBL436535
8.52	EC50	3	nM	CHEMBL491923
8.52	EC50	3	nM	CHEMBL492090

PubChem BioAssay actives

865 with measured affinity, of 1588 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R)-1-(6-ethyl-2-imidazol-1-ylpyrimidin-4-yl)pyrrolidin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0001	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R)-1-(2-imidazol-1-yl-6-methylpyrimidin-4-yl)pyrrolidin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0001	uM
methyl (3S)-3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)piperazine-1-carboxylate	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0002	uM
(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid	241425: Inhibition of inducible nitric oxide synthase in activated macrophages	ic50	0.0002	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-(6-fluoro-2-pyridinyl)-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0003	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R)-1-(2-imidazol-1-ylpyrimidin-4-yl)pyrrolidin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0003	uM
(2R)-N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(2-imidazol-1-yl-6-methylpyrimidin-4-yl)pyrrolidine-2-carboxamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0003	uM
methyl 3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)piperazine-1-carboxylate	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0004	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-benzoyl-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)-4-(2-phenylmethoxyacetyl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(6-chloro-2-imidazol-1-ylpyrimidin-4-yl)piperidin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
(2R)-N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(6-ethyl-2-imidazol-1-ylpyrimidin-4-yl)pyrrolidine-2-carboxamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-(2-imidazol-1-ylpyrimidin-4-yl)morpholin-3-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)-4-methylpiperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)piperidin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
(2R)-N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(2-imidazol-1-ylpyrimidin-4-yl)pyrrolidine-2-carboxamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0005	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0006	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-(furan-2-ylmethyl)-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0006	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)-4-methylsulfonylpiperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0007	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-(furan-2-carbonyl)-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0007	uM
2-[1-(2-imidazol-1-ylpyrimidin-4-yl)piperidin-2-yl]-N-[(4-methoxyphenyl)methyl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0008	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R)-4-(2-imidazol-1-yl-6-methylpyrimidin-4-yl)-1-(2-methylpropanoyl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0008	uM
benzyl 3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)piperazine-1-carboxylate	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0008	uM
ethyl 2-[3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-1-yl]acetate	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0009	uM
3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)-N-phenylpiperazine-1-carboxamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0009	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-benzyl-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0010	uM
3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)-N-methylpiperazine-1-carboxamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0010	uM
3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-N-benzyl-4-(2-imidazol-1-ylpyrimidin-4-yl)piperazine-1-carboxamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0010	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)-4-(3-methylbutyl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0010	uM
2-[4-acetyl-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0010	uM
propan-2-yl 3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)piperazine-1-carboxylate	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0010	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-[5-(dimethylamino)naphthalen-1-yl]sulfonyl-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0011	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(6-chloro-2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]acetamide	92002: Inhibitory activity against the partially purified human Inducible nitric oxide synthase	ic50	0.0011	uM
phenyl 3-[2-(1,3-benzodioxol-5-ylmethylamino)-2-oxoethyl]-4-(2-imidazol-1-ylpyrimidin-4-yl)piperazine-1-carboxylate	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0014	uM
N-[(3,4-dimethoxyphenyl)methyl]-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)piperidin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0015	uM
(2S)-2-amino-5-[(N’-methylcarbamimidoyl)amino]pentanoic acid	669683: Inhibition of human recombinant iNOS assessed as conversion of [3H]L-arginine to [3H]L-citrulline preincubated for 15 mins measured after 45 mins by liquid scintillation counting	ic50	0.0018	uM
(1S,5S,6R,7R)-7-chloro-5-methyl-2-azabicyclo[4.1.0]hept-2-en-3-amine;hydrochloride	667551: Inhibition of human iNOS	ki	0.0018	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[4-(2-imidazol-1-yl-6-methylpyrimidin-4-yl)-1-(2-methylpropanoyl)piperazin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0019	uM
5,8-difluoro-2-(furan-2-yl)-1,2-dihydroquinazolin-4-amine	92004: Inhibitory activity of compound against human inducible nitric oxide synthase	ic50	0.0020	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)azepan-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0020	uM
N-(3-chlorophenyl)-N-[(7,8-difluoro-2-oxo-1H-quinolin-4-yl)methyl]-4-methyl-1,3-thiazole-5-carboxamide	349841: Inhibition of human iNOS expressed in HEK293 cells assessed as NO production by transient transfection assay	ec50	0.0020	uM
(1S,5S,6R,7R)-7-chloro-5-methyl-2-azabicyclo[4.1.0]hept-2-en-3-amine	2007178: Inhibition of human iNOS overexpressed in baculovirus infected Sf21 cells assessed as inhibition constant	ki	0.0020	uM
2-[4-(benzenesulfonyl)-1-(2-imidazol-1-ylpyrimidin-4-yl)piperazin-2-yl]-N-(1,3-benzodioxol-5-ylmethyl)acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0027	uM
N-[(4-fluorophenyl)methyl]-2-[1-(2-imidazol-1-ylpyrimidin-4-yl)piperidin-2-yl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0030	uM
N-(3-chlorophenyl)-N-[(7,8-difluoro-2-oxo-1H-quinolin-4-yl)methyl]-3-methylimidazole-4-carboxamide	349841: Inhibition of human iNOS expressed in HEK293 cells assessed as NO production by transient transfection assay	ec50	0.0030	uM
N-(3-chlorophenyl)-N-[(7,8-difluoro-2-oxo-1H-quinolin-4-yl)methyl]-3,5-dimethyl-1,2-oxazole-4-carboxamide	349841: Inhibition of human iNOS expressed in HEK293 cells assessed as NO production by transient transfection assay	ec50	0.0030	uM
2-[1-(2-imidazol-1-ylpyrimidin-4-yl)piperidin-2-yl]-N-[2-(4-methoxyphenyl)ethyl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0035	uM
2-[1-(2-imidazol-1-ylpyrimidin-4-yl)piperidin-2-yl]-N-[(3-methoxyphenyl)methyl]acetamide	280474: Inhibition of cytokine-induced iNOS expressed in human A172 cells assessed as inhibition of NO formation	ic50	0.0037	uM
N-(1,3-benzodioxol-5-ylmethyl)-2-[2-(2-imidazol-1-yl-6-methylpyrimidin-4-yl)pyrrolidin-1-yl]-N-methylethanamine	626385: Inhibition of human iNOS expressed in human HEK293 cells assessed as nitrite accumulation after 18 hrs by 2,3-diaminonapthalene assay	ec50	0.0040	uM
2-[(1R)-3-amino-1-phenylpropyl]sulfanyl-6-methylpyridine-3-carbonitrile;(E)-but-2-enedioic acid	589858: Inhibition of human recombinant iNOS	ic50	0.0040	uM

CTD chemical–gene interactions

336 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Lipopolysaccharides	increases chemical synthesis, increases activity, affects cotreatment, decreases expression, increases expression (+5 more)	28
Nitric Oxide	decreases reaction, increases chemical synthesis, decreases expression, affects cotreatment, decreases methylation (+10 more)	24
Resveratrol	decreases stability, decreases expression, decreases abundance, affects cotreatment, decreases reaction (+4 more)	8
Benzo(a)pyrene	affects methylation, affects expression, affects reaction, decreases expression, decreases reaction (+2 more)	7
Quercetin	decreases reaction, increases expression, affects cotreatment, decreases expression	7
Particulate Matter	affects methylation, decreases methylation, increases expression, affects response to substance, increases abundance	7
Plant Extracts	decreases reaction, increases expression, decreases chemical synthesis, increases reaction, decreases expression (+1 more)	6
pyrrolidine dithiocarbamic acid	increases expression, affects cotreatment, decreases reaction	5
Air Pollutants	increases expression, affects response to substance, affects abundance, decreases reaction, affects methylation (+2 more)	5
Glucose	decreases reaction, affects expression, increases expression, affects reaction	5
Tetradecanoylphorbol Acetate	increases reaction, decreases reaction, increases expression, affects cotreatment	5
Valproic Acid	affects cotreatment, decreases expression, increases expression	5
Cadmium	increases abundance, increases expression, increases secretion, decreases reaction	4
Cadmium Chloride	affects cotreatment, decreases reaction, increases activity, increases abundance, increases expression	4
bisphenol A	increases expression, decreases reaction	3
arsenite	increases activity, increases expression	3
sodium arsenite	decreases expression, increases expression	3
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	increases expression, increases reaction, affects cotreatment, decreases expression, decreases reaction	3
SB 203580	affects cotreatment, decreases reaction, increases expression	3
U 0126	decreases expression, decreases reaction, increases expression	3
Acetylcysteine	affects cotreatment, decreases expression, decreases reaction, increases expression	3
Curcumin	decreases reaction, increases expression, increases activity	3
Cycloheximide	decreases reaction, increases expression, affects cotreatment	3
Doxorubicin	decreases expression, increases expression, increases reaction	3
Chlorpyrifos	increases expression	3
Glucosamine	increases reaction, affects cotreatment, decreases expression, decreases reaction, increases expression	3
Melitten	decreases reaction, increases chemical synthesis, increases expression, decreases expression	3
Methotrexate	decreases reaction, increases chemical synthesis, increases expression	3
Mustard Gas	increases expression, decreases reaction, decreases expression	3
Nitroprusside	decreases reaction, increases chemical synthesis, increases expression, affects cotreatment, decreases activity	3

ChEMBL screening assays

263 unique, capped per target: 255 binding, 5 functional, 2 admet, 1 unclassified

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1003684	Binding	Selectivity ratio, EC50 for human iNOS over EC50 for human nNOS	Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. — *J Med Chem*
CHEMBL4346022	Unclassified	Selectivity index, ratio of Ki for human iNOS expressed in Escherichia coli expression system to Ki for human nNOS expressed in Escherichia coli expression system	First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate. — *J Med Chem*
CHEMBL4346021	ADMET	Inhibition of human iNOS expressed in Escherichia coli expression system assessed as reduction in NO production in presence of L-arginine measured for 30 sec by hemoglobin capture assay	First Contact: 7-Phenyl-2-Aminoquinolines, Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors That Target an Isoform-Specific Aspartate. — *J Med Chem*

Cellosaurus cell lines

7 cell lines: 6 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1YS	Abcam HeLa NOS2 KO	Cancer cell line	Female
CVCL_B7GG	603B-iNOS antisense	Transformed cell line	Female
CVCL_B8LI	Abcam HCT 116 NOS2 KO	Cancer cell line	Male
CVCL_B8ZI	Abcam MCF-7 NOS2 KO	Cancer cell line	Female
CVCL_B9NN	Abcam A-549 NOS2 KO	Cancer cell line	Male
CVCL_TA85	HAP1 NOS2 (-) 1	Cancer cell line	Male
CVCL_TA86	HAP1 NOS2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00000374	Phase 4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	Phase 4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	Phase 4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	Phase 4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	Phase 4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	Phase 4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	Phase 4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	Phase 4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	Phase 4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	Phase 4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	Phase 4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	Phase 4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	Phase 4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	Phase 4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	Phase 4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	Phase 4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	Phase 4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	Phase 4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	Phase 4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	Phase 4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	Phase 4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	Phase 4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	Phase 4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	Phase 4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	Phase 4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	Phase 4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	Phase 4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	Phase 4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	Phase 4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	Phase 4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	Phase 4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	Phase 4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	Phase 4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	Phase 4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	Phase 4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	Phase 4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	Phase 4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	Phase 4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	Phase 4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	Phase 4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
NCT00177580	Phase 4	COMPLETED	Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
NCT00182442	Phase 4	COMPLETED	Cognition, Functioning and Quality of Life
NCT00182494	Phase 4	UNKNOWN	Diabetes Prevention Program in Schizophrenia [DPPS]
NCT00183625	Phase 4	COMPLETED	Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients
NCT00186771	Phase 4	UNKNOWN	Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
NCT00190749	Phase 4	COMPLETED	Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
NCT00191555	Phase 4	COMPLETED	Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment
NCT00194025	Phase 4	COMPLETED	Valproate in Late Life Schizophrenia
NCT00199940	Phase 4	COMPLETED	Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness
NCT00202306	Phase 4	COMPLETED	Indicated Prevention of Psychotic Disorders With Low-dose Lithium
NCT00203788	Phase 4	COMPLETED	Improving Work Outcome in People With Recent-onset Schizophrenia
NCT00204061	Phase 4	COMPLETED	Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis
NCT00205660	Phase 4	COMPLETED	Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
NCT00206102	Phase 4	COMPLETED	A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
NCT00208143	Phase 4	COMPLETED	Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
NCT00208169	Phase 4	COMPLETED	Abilify Therapy for Reducing Comorbid Substance Abuse
NCT00214578	Phase 4	COMPLETED	Seroquel on Glucose Metabolism
NCT00215579	Phase 4	COMPLETED	Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00216528	Phase 4	COMPLETED	A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
NCT00216632	Phase 4	COMPLETED	A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for NOS2 across ~30M SureChEMBL compounds — explore on Sugi Predict.